Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Duloxetine Versus Placebo for Osteoarthritis Knee Pain

Phase 3

Completed

Conditions: Osteoarthritis Knee Pain

Interventions: Drug: placebo
Drug: Duloxetine

First Posted Date: 2006-12-07

Last Posted Date: 2009-08-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 231

Registration Number: NCT00408421

Locations: 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania

Duloxetine Versus Placebo in Chronic Low Back Pain

Phase 3

Completed

Conditions: Back Pain Without Radiation

Interventions: Drug: Duloxetine
Drug: Placebo

First Posted Date: 2006-12-07

Last Posted Date: 2009-12-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 404

Registration Number: NCT00408876

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Tampa, Florida, United States

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

Phase 3

Completed

Conditions: Turner Syndrome

First Posted Date: 2006-12-04

Last Posted Date: 2006-12-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 100

Registration Number: NCT00406926

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States

A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: duloxetine hydrochloride
Drug: placebo

First Posted Date: 2006-12-04

Last Posted Date: 2010-09-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 370

Registration Number: NCT00406848

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico

Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany

Phase 4

Completed

Conditions: Attention Deficit Hyperactivity Disorder
Oppositional Defiant Disorder

Interventions: Drug: Placebo
Drug: Atomoxetine

First Posted Date: 2006-12-04

Last Posted Date: 2010-02-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 181

Registration Number: NCT00406354

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munchen, Germany

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

Phase 4

Completed

Conditions: Bipolar I Disorder

Interventions: Drug: placebo
Drug: olanzapine
Drug: divalproex

First Posted Date: 2006-11-22

Last Posted Date: 2009-06-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 202

Registration Number: NCT00402324

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hialeah, Florida, United States

Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

Phase 1

Completed

Conditions: Glioblastoma Multiforme
Glioblastoma
Gliosarcoma

Interventions: Drug: enzastaurin
Drug: temozolomide
Radiation: radiation therapy

First Posted Date: 2006-11-22

Last Posted Date: 2020-08-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT00402116

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Francisco, California, United States

Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2006-11-22

Last Posted Date: 2010-02-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 133

Registration Number: NCT00402051

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorders

Interventions: Drug: olanzapine
Behavioral: Wellness education
Drug: amantadine
Drug: metformin
Drug: zonisamide

First Posted Date: 2006-11-22

Last Posted Date: 2009-10-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 199

Registration Number: NCT00401973

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation

Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: insulin lispro LM
Drug: Insulin Biphasic Aspart 30/70
Drug: insulin lispro MM

First Posted Date: 2006-10-29

Last Posted Date: 2010-07-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 302

Registration Number: NCT00393705

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Konya, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy